NORCROSS, Ga., March 21, 2016 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced FDA clearance for the latest release of ImmuLINK® (v1.7), the Company’s centralized data management solution that supports greater testing efficiency and safety within transfusion medicine.
The latest release of ImmuLINK includes a molecular module that helps users manage the workflow associated with running Immucor’s PreciseType HEA test, reducing manual data entry and significantly increasing the number of tests a lab may perform and report. The PreciseType HEA test is the first and only FDA-approved molecular typing solution and is eligible for reimbursement across the U.S.
ImmuLINK v1.7 enhancements, specifically tailored to PreciseType HEA users, include:
Additionally, ImmuLINK v1.7 now aggregates all serology and molecular IVD test results from the Echo®, NEO® and PreciseType platforms. ImmuLINK v1.7 generates a single report with a complete donor or patient testing history.
“Immucor is the only company offering a total immunohematology solution across serologic and molecular technologies that includes manual and automated reagents, instrumentation, data management, QC and an educational resource network meeting the needs of the smallest to largest hospitals, blood centers and other testing sites. ImmuLINK has always been a broad data management solution that manages serological test results and now, with the release of ImmuLINK v1.7, also manages results generated by our FDA-approved red cell genotyping assay, the PreciseType HEA test,” stated Keith Chaitoff, Immucor’s Chief Marketing Officer. “With ImmuLINK, customers save time, improve testing efficiency and increase test result accessibility so that a patient may safely receive the best matched donor blood.”
The FDA-cleared molecular module of ImmuLINK reflects a new release for customers in the United States and Canada. Customers in Europe and beyond Europe will continue to use an existing CE-marked molecular module.
Immucor’s ImmuLINK software suite is a centralized data management solution designed specifically for donor centers, reference labs and hospitals and is focused on transfusion medicine. ImmuLINK enables users to manage complex serology and molecular testing in remote sites with a single user interface from a core lab location. The software suite provides an easier and more efficient way to view, check and manage all blood bank test data and connect to a LIS. Find more information about ImmuLINK at http://www.immucor.com/en-us/Products/Pages/ImmuLINK.aspx
To request a demonstration or webinar of any module of ImmuLINK contact:
In the United States: Lori Giannetta, BS, MT (ASCP) at email@example.com or an Immucor Blood Bank Business Manager at 855-IMMUCOR
In Canada: 800-565-0653 or email DBLCustomerService@immucor.com
In China: firstname.lastname@example.org
In India: 91-11-40516025 or email@example.com
In Japan: 0120-16-4521 or firstname.lastname@example.org
All other countries: email@example.com or your local Immucor representative
About PreciseType HEA
The Immucor PreciseType HEA test rapidly and accurately predicts blood compatibility between donors and patients to help prevent mismatches that can cause serious, potentially life-threatening reactions. The test works by detecting genes that govern the expression of 38 antigens that can appear on the surface of red blood cells. The test is manufactured by Immucor’s wholly owned subsidiary, BioArray Solutions. The Scientist ranked PreciseType HEA among the Top 10 Innovations in 2014. Find more information at http://www.immucor.com/en-us/Products/Pages/PreciseType-HEA.aspx
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, please visit our website at www.immucor.com.
FOR IMMEDIATE RELEASE
CONTACT: Michele Howard